Lindsay E Kelderhouse1, Sakkarapalayam Mahalingam1, Philip S Low2. 1. Department of Chemistry, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA. 2. Department of Chemistry, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA. plow@purdue.edu.
Abstract
PURPOSE: Although current therapies for many inflammatory/autoimmune diseases are effective, a significant number of patients still exhibit only partial or negligible responses to therapeutic intervention. Since prolonged use of an inadequate therapy can result in both progressive tissue damage and unnecessary expense, methods to identify nonresponding patients are necessary. PROCEDURES: Four murine models of inflammatory disease (rheumatoid arthritis, ulcerative colitis, pulmonary fibrosis, and atherosclerosis) were induced, treated with anti-inflammatory agents, and evaluated for inflammatory response. The mice were also injected intraperitoneally with OTL0038, a folate receptor-targeted near-infrared dye that accumulates in activated macrophages at sites of inflammation. Uptake of OTL0038 in inflamed lesions was then correlated with clinical measurements of disease severity. RESULTS: OTL0038 accumulated at sites of inflammation in all four animal models. More importantly, changes in lesion-associated OTL0038 preceded changes in clinical symptoms in mice treated with all anti-inflammatory drugs examined. CONCLUSION: OTL0038 has the ability to predict responses to multiple therapies in four murine models of inflammation.
PURPOSE: Although current therapies for many inflammatory/autoimmune diseases are effective, a significant number of patients still exhibit only partial or negligible responses to therapeutic intervention. Since prolonged use of an inadequate therapy can result in both progressive tissue damage and unnecessary expense, methods to identify nonresponding patients are necessary. PROCEDURES: Four murine models of inflammatory disease (rheumatoid arthritis, ulcerative colitis, pulmonary fibrosis, and atherosclerosis) were induced, treated with anti-inflammatory agents, and evaluated for inflammatory response. The mice were also injected intraperitoneally with OTL0038, a folate receptor-targeted near-infrared dye that accumulates in activated macrophages at sites of inflammation. Uptake of OTL0038 in inflamed lesions was then correlated with clinical measurements of disease severity. RESULTS: OTL0038 accumulated at sites of inflammation in all four animal models. More importantly, changes in lesion-associated OTL0038 preceded changes in clinical symptoms in mice treated with all anti-inflammatory drugs examined. CONCLUSION: OTL0038 has the ability to predict responses to multiple therapies in four murine models of inflammation.
Authors: E Tsakonas; A A Fitzgerald; M A Fitzcharles; A Cividino; J C Thorne; A M'Seffar; L Joseph; C Bombardier; J M Esdaile Journal: J Rheumatol Date: 2000-03 Impact factor: 4.666
Authors: Wei Xia; Andrew R Hilgenbrink; Eric L Matteson; Michael B Lockwood; Ji-Xin Cheng; Philip S Low Journal: Blood Date: 2008-10-24 Impact factor: 22.113
Authors: Nynke A Jager; Johanna Westra; Gooitzen M van Dam; Nato Teteloshvili; René A Tio; Jan-Cees Breek; Riemer H J A Slart; Hendrikus Boersma; Phillip S Low; Marc Bijl; Clark J Zeebregts Journal: J Nucl Med Date: 2012-06-29 Impact factor: 10.057
Authors: Brian Z Bentz; Sakkarapalayam M Mahalingam; Daniel Ysselstein; Paola C Montenegro Larrea; Jason R Cannon; Jean-Christophe Rochet; Philip S Low; Kevin Webb Journal: IEEE Trans Med Imaging Date: 2020-02-06 Impact factor: 10.048
Authors: Yingwen Hu; Bingbing Wang; Jiayin Shen; Stewart A Low; Karson S Putt; Hans W M Niessen; Eric L Matteson; Linda Murphy; Clemens Ruppert; Gerrit Jansen; Stephen J Oliver; Yang Feng; Dimiter S Dimitrov; Cheryl Nickerson-Nutter; Philip S Low Journal: Arthritis Res Ther Date: 2019-06-07 Impact factor: 5.156
Authors: Maarten M Steinz; Aiarpi Ezdoglian; Fatemeh Khodadust; Carla F M Molthoff; Madduri Srinivasarao; Philip S Low; Gerben J C Zwezerijnen; Maqsood Yaqub; Wissam Beaino; Albert D Windhorst; Sander W Tas; Gerrit Jansen; Conny J van der Laken Journal: Front Immunol Date: 2022-02-02 Impact factor: 7.561
Authors: Durga M S H Chandrupatla; Gerrit Jansen; Ricardo Vos; Mariska Verlaan; Qingshou Chen; Philip S Low; Albert D Windhorst; Adriaan A Lammertsma; Conny J van der Laken; Carla F M Molthoff Journal: Arthritis Res Ther Date: 2017-05-31 Impact factor: 5.156
Authors: Durga M S H Chandrupatla; Carla F M Molthoff; Adriaan A Lammertsma; Conny J van der Laken; Gerrit Jansen Journal: Drug Deliv Transl Res Date: 2019-02 Impact factor: 4.617
Authors: L J Lauwerends; H Abbasi; T C Bakker Schut; P B A A Van Driel; J A U Hardillo; I P Santos; E M Barroso; S Koljenović; A L Vahrmeijer; R J Baatenburg de Jong; G J Puppels; S Keereweer Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-01 Impact factor: 10.057